"We Envision Growth Strategies Most Suited
to Your Business"
The coronavirus pandemic, also known as the Covid-19 pandemic, has exhibited far-reaching consequences beyond the spread of the infection and futile efforts to quarantine it. Concerns have now shifted towards unveiling an effective vaccine to control this infamous pandemic. According to the Johns Hopkins University & Medicine’s Coronavirus Resource Center, as of April 13th, there were around 120,000 deaths and more than 1.9 million cases attributed to coronavirus. Experts believe that it would take approximately 12-18 months to create a new vaccine. Hence, several companies are participating in the rat race to develop one owing to the rapid spread of the disease. This information is given in a recent report, titled, “Covid-19 Vaccine– Pipeline Review, 2020” by Fortune Business Insights™.
Sinovac to Conduct Human Clinical Trial on SARS-CoV-2 Vaccine Candidate
In April 2020, Sinovac Biotech Ltd., a biopharmaceutical company headquartered in China, bagged approval to conduct a human clinical trial on SARS-CoV-2 vaccine candidate. It is inactive. The development of this vaccine began by the end of January 2020. Scientists working in Sinovac were racing to finish the comprehensive preclinical studies by collaborating with prominent research institutions in China. Amongst those studies, an animal challenge study proves that the vaccine candidate is capable of protecting animals without the requirement of antibody-dependent enhancement. Besides, this candidate would be able to neutralize virus strains from numerous countries. It would also support the potential of this vaccine to prevent the spread of Covid-19 worldwide.
Researchers of Imperial College Develop mRNA Vaccine Candidate to Combat Against Covid-19
In March 2020, the officials of Imperial College London, a world-class university with a mission to benefit society through excellence in business, medicine, engineering, and science, announced that the researchers of the department of infectious disease are taking ground-breaking efforts in developing a mRNA vaccine to fight against Covid-19. The academic institution claims to possess the technology required to create a vaccine with top speed that has never been witnessed before. mRNA vaccines are anticipated to be cheaper and faster to manufacture backed by their synthetic nature. They also do not contain any attenuated or live virus. The candidate vaccine was developed just within 14 days of receiving the sequence from China. The officials are planning to move towards clinical trial in the upcoming summer as it was being tested on animals since February 10th.
To get a detailed report summary and research scope of this market, click here:
https://www.fortunebusinessinsights.com/covid-19-vaccine-pipeline-review-2020-102651
Medicago Discovers New Virus-Like Particle (VLP) of Covid-19
In March 2020, Medicago, a leading clinical-stage biopharmaceutical company headquartered in the U.S., declared the production of a Virus-Like Particle (VLP) of Covid-19. It was developed only 20 days after procuring the SARS-CoV-2 gene. It is considered to be the first step in creating a vaccine for controlling the pandemic. The VLP will soon undergo preclinical testing for efficacy and safety. Once it is done, the experts of the company would try to begin human trials of the vaccine till summer 2020 (July/August). But this will be done only after discussing thoroughly with the concerned health agencies.
The company is also developing antibodies against SARS-CoV-2 by using its technology platform. To do so, it has joined hands with the Infectious Disease Research Centre under Laval University. The centre is headed by Dr. Gary Kobinger who had previously helped in the development of treatment options and a vaccine for Ebola. The SARS-CoV-2 antibodies may potentially be used to treat people affected by the virus. The Canadian Institutes for Health Research (CIHR) is currently funding the research in part.
Fortune Business Insights™ provides a list of all the companies who are persistently striving to conduct research and development activities for creating a new vaccine for Covid-19:
A few of the most recent industry developments:
Further Report Findings-